About 270 results

ALLMedicine™ Schizophreniform Disorder Center

Research & Reviews  90 results

Pineal morphology of the clinical high-risk state for psychosis and different psychotic...
Schizophrenia Research; Takahashi T, Wood SJ et. al.

Apr 30th, 2022 - Pineal volume reductions have been reported in schizophrenia and clinical high-risk states for the development of psychosis, supporting the role of melatonin dysregulation in the pathophysiology of psychosis. However, it remains unclear whether pi...

Premorbid characteristics of patients with DSM-IV psychotic disorders.
Comprehensive Psychiatry; Widing L, Simonsen C et. al.

Apr 7th, 2022 - Psychotic disorder not otherwise specified (PNOS) is considered part of the psychosis spectrum, together with schizophrenia spectrum disorders (SSD) and psychotic bipolar spectrum disorders (PBD). The atypical clinical presentations of PNOS condit...

Schizophreniform Disorder

Apr 1st, 2022 - Schizophreniform disorder is characterized by symptoms identical to those of schizophrenia but that last ≥ 1 month but < 6 months.

The Disease Recovery Evaluation and Modification (DREaM) study: Effectiveness of palipe...
Schizophrenia Research; Alphs L, Brown B et. al.

Mar 6th, 2022 - We report primary results of the Disease Recovery Evaluation and Modification (DREaM) study, a randomized, open-label, delayed-start trial designed to compare the effectiveness of paliperidone palmitate (PP) versus oral antipsychotics (OAP) in del...

Frontotemporal thalamic connectivity in schizophrenia and schizotypal personality disor...
Psychiatry Research. Neuroimaging; Szeszko PR, Gohel S et. al.

Mar 4th, 2022 - Schizotypal personality disorder (SPD) resembles schizophrenia, but with attenuated brain abnormalities and the absence of psychosis. The thalamus is integral for processing and transmitting information across cortical regions and widely implicate...

see more →

Clinicaltrials.gov  11 results

A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia...

Dec 3rd, 2021 - A Prospective, matched-control, Randomized (assignment of study drug by chance), open-label, flexible-dose, study in participants with recent-onset schizophrenia or schizophreniform disorder to compare disease progression and disease modification ...

A Study of Dose-response Relationship and the Evidence Based Multisensory Stimulation Intervention

Aug 19th, 2021 - This was a prospective randomized controlled trial with parallel groups following the Consolidated Standards of Reporting Trials and was approved by the Institutional Review Board of Jianan Mental Health Hospital (approval number Taiwan Nurses Ass...

Double Blind, Placebo-Controlled, Randomised Investigation of Ondansetron in Schizophrenia

Oct 14th, 2020 - Ondansetron is a medication currently approved by the Australian Therapeutic Goods Administration for the treatment of drug-induced vomiting and nausea. Beyond this traditional use there have been several case reports and small clinical trials adv...

Open-label Ziprasidone Study for Psychosis Treatment in Adolescents

Jan 13th, 2017 - This study is an open-label assessment of the feasibility of treating adolescents with psychotic disorders (schizophreniform disorder, schizoaffective disorder, psychosis not otherwise specified [NOS], major depressive disorder with psychotic feat...

NRX-1074 in Early Course Schizophrenia

Feb 5th, 2016 - Investigators propose to conduct a 4-week, randomized, double-blind, placebo-controlled trial in which NRX-1074 will be intravenously administered twice. Subjects will be 62 stable patients ages 18-50 within five years of onset of schizophrenia, t...

see more →

News  7 results

New Combination Med for Severe Mental Illness Tied to Less Weight Gain

Apr 19th, 2022 - Olanzapine plus samidorphan (Lybalvi) vs olanzapine alone is associated with less weight gain while achieving similar clinical outcomes in patients with recent-onset severe mental illness, new research suggests. However, least one expert says the ...

Novel Drug Offers Rapid Relief From Agitation in Serious Mental Illness

May 5th, 2021 - An investigational, orally dissolving film formulation of dexmedetomidine (BXCL501, BioXcel Therapeutics) may offer rapid relief from acute agitation related to schizophrenia or bipolar disorder (BD), results of two phase 3, randomized, placebo-co...

Schizophrenia in Youth Not a Neurodegenerative Illness

Oct 16th, 2018 - Young patients with recent-onset schizophrenia do not show signs of cognitive deterioration or disruption of ongoing brain development in the first years following illness onset, new research shows. Results of a large longitudinal study show that ...

First-episode psychosis readmission risk predicted by DALI tool
Tara Haelle

Jun 10th, 2013 - Screening first-episode psychotic patients with a 6-minute assessment tool provides a more reliable indication of a patient’s risk of readmission than urinalysis, according to a new study in Schizophrenia Research. Patients scoring in the "at-risk.

Clozapine for First-Episode Schizophrenia: 9 Years Later

Apr 4th, 2011 - Clozapine v. Chlorpromazine in Treatment-Naive, First-Episode Schizophrenia: 9-Year Outcomes of a Randomised Clinical Trial Girgis RR, Phillips MR, Li X, et al Br J Psychiatry. 2011 Feb 3. [Epub ahead of print] Study Summary The study authors comp...

see more →